Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients
A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma
Sponsor: Cytran
This PHASE3 trial investigates HIV Infections and Sarcoma, Kaposi and is currently completed. Cytran leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cytran
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antwerp, Belgium, Atlanta, United States, Baltimore, United States, Boston, United States, Brussels, Belgium, Chicago, United States, Cleveland, United States, Columbus, United States, Darlinghurst, Australia, Indianapolis, United States and 20 more location s